Managing Side Effects and Timing of Radium-223, PARP Inhibitors

48 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
A regional roundtable discussion, moderated by Mark Delworth, MD, The Urology Group, explored the evolving landscape of advanced prostate cancer management, including imaging innovations, treatment sequencing, biomarker integration, and patient-centered decision-making. Dr. Delworth was joined by other practitioners at The Urology Group, including Brian Minnillo, MD; Robert Larke, MD; Brooke Edwards, MD; and Stephen Bennett, MD.

In the fourth segment, the panel considers the use of radium-223, PARP inhibitors, and other advanced therapies for patients with metastatic castration-resistant prostate cancer. They address sequencing challenges, patient selection, side effect management, and the importance of germline and somatic testing to guide therapy.
Categoria
Oncology
Commenta per primo questo video.

Prossimo